148 related articles for article (PubMed ID: 11583336)
1. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
Margaglione M; Brancaccio V; Ciampa A; Di Minno G
Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
[No Abstract] [Full Text] [Related]
2. Genetic modulation of oral anticoagulation with warfarin.
Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G
Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854
[TBL] [Abstract][Full Text] [Related]
3. Avoiding overanticoagulation: pharmacogenomics or pragmatism?
Baglin T
Thromb Haemost; 2001 May; 85(5):945-6. PubMed ID: 11372698
[No Abstract] [Full Text] [Related]
4. Genetic susceptibility to hemorrhagic complications during warfarin therapy.
Tabrizi AR; Freeman BD; Buchman TG; Zehnbauer BA
Surgery; 2001 May; 129(5):645-6. PubMed ID: 11331459
[No Abstract] [Full Text] [Related]
5. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
6. Genetic control of anticoagulation.
Mannucci PM
Lancet; 1999 Feb; 353(9154):688-9. PubMed ID: 10073506
[No Abstract] [Full Text] [Related]
7. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
8. Warfarin dose requirement and CYP2C9 polymorphisms.
Halkin H; Lubetsky A
Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
[No Abstract] [Full Text] [Related]
9. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
Ablin J; Cabili S; Lagziel A; Peretz H
Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
[No Abstract] [Full Text] [Related]
10. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
[TBL] [Abstract][Full Text] [Related]
11. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9 polymorphism and warfarin dose requirements.
Daly AK; Day CP; Aithal GP
Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680
[No Abstract] [Full Text] [Related]
13. Major bleeding caused by warfarin in a genetically susceptible patient.
Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y
Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436
[TBL] [Abstract][Full Text] [Related]
14. Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype.
Dericioglu N; Babaoglu MO; Saygi S; Bozkurt A; Yasar U
Ann Pharmacother; 2004 May; 38(5):899. PubMed ID: 15039471
[No Abstract] [Full Text] [Related]
15. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
[TBL] [Abstract][Full Text] [Related]
16. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
Takahashi H; Wilkinson GR; Padrini R; Echizen H
Clin Pharmacol Ther; 2004 May; 75(5):376-80. PubMed ID: 15116049
[No Abstract] [Full Text] [Related]
18. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
[No Abstract] [Full Text] [Related]
19. Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction.
Kunze KL; Trager WF
Drug Metab Dispos; 1996 Apr; 24(4):429-35. PubMed ID: 8801058
[TBL] [Abstract][Full Text] [Related]
20. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
Taube J; Halsall D; Baglin T
Blood; 2000 Sep; 96(5):1816-9. PubMed ID: 10961881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
